OPTN/SRTR 2017 annual data report: kidney.
Am J Transpl. 2019; 19: 19-123
Treatment with glucocorticoids or calcineurin inhibitors in primary FSGS.
Clin J Am Soc Nephrol. 2016; 11: 386-394
Efficacy and safety of calcineurin inhibitor treatment for IgA nephropathy: a meta-analysis.
BMC Nephrol. 2017; 18: 61https://doi.org/10.1186/s12882-017-0467-z
A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis.
Kidney Int. 2019; 95: 219-231
Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial.
Kidney Int. 2001; 59: 1484-1490
The natural history of chronic allograft nephropathy.
N Engl J Med. 2003; 349: 2326-2333
Biological effects of cyclosporin A: a new antilymphocytic agent.
Agents Actions. 1976; 6: 468-475
Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers.
Lancet. 1979; 2: 1033-1036
FK 506 for liver, kidney, and pancreas transplantation.
Lancet. 1989; 2: 1000-1004
Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A.
Nature. 1991; 352: 803-807
Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation.
Nature. 1992; 357: 695-697
FK-506- and CsA-sensitive activation of the interleukin-2 promoter by calcineurin.
Nature. 1992; 357: 692-694
Large within-day variation in cyclosporine absorption: circadian variation or food effect?.
Clin J Am Soc Nephrol. 2006; 1: 462-466
Full Prescribing Information for Prograf. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210115s000,050708s047,050709s040lbl.pdf. Accessed September 7, 2019.
The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups.
Clin Pharmacol Ther. 2001; 69: 24-31
CYP3A5 polymorphism in Mexican renal transplant recipients and its association with tacrolimus dosing.
Arch Med Res. 2012; 43: 283-287
Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium.
Transplantation. 2011; 91: 300-308
Genomewide association study of tacrolimus concentrations in African American kidney transplant recipients identifies multiple CYP3A5 alleles.
Am J Transpl. 2016; 16: 574-582
Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients.
Ther Drug Monit. 2010; 32: 394-404
The donor ABCB1 (MDR-1) C3435T polymorphism is a determinant of the graft glomerular filtration rate among tacrolimus treated kidney transplanted patients.
J Hum Genet. 2015; 60: 273-276
Therapeutic monitoring of calcineurin inhibitors for the nephrologist.
Clin J Am Soc Nephrol. 2007; 2: 374-384
Tacrolimus whole blood concentrations correlate closely to side-effects in renal transplant recipients.
Br J Clin Pharmacol. 1999; 48: 445-448
Tacrolimus trough levels after month 3 as a predictor of acute rejection following kidney transplantation: a lesson learned from DeKAF genomics.
Transpl Int. 2013; 26: 982-989
Cyclosporin in therapeutic doses increases renal allograft vascular resistance.
Lancet. 1986; 2: 477-479
Effects of endothelin receptor antagonist on cyclosporine-induced vasoconstriction in isolated rat renal arterioles.
J Clin Invest. 1993; 91: 2144-2149
Arginine feeding modifies cyclosporine nephrotoxicity in rats.
J Clin Invest. 1993; 92: 1859-1865
Increased risk of thrombotic microangiopathy in patients receiving a cyclosporin-sirolimus combination.
Am J Transpl. 2004; 4: 946-952
Long-term outcome of renal transplantation from older donors.
N Engl J Med. 2006; 354: 343-352
Interstitial fibrosis in renal allografts after 12 to 46 months of cyclosporin treatment: beneficial effect of low doses in early post-transplantation period.
Lancet. 1984; 2: 950-954
Pharmacokinetics and nephrotoxicity of cyclosporine in renal transplant recipients.
Transplantation. 1985; 40: 261-265
An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group.
Transplantation. 1996; 62: 900-905
Tacrolimus and nonsteroidal anti-inflammatory drugs: an association to be avoided.
Am J Nephrol. 2005; 25: 327-334
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression.
Nat Genet. 2001; 27: 383-391
Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement.
Transplantation. 2002; 74: 1486-1489
Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus.
Clin Pharmacol Ther. 2003; 74: 245-254
Results of ASERTAA, a randomized prospective crossover pharmacogenetic study of immediate-release versus extended-release tacrolimus in African American kidney transplant recipients.
Am J Kidney Dis. 2018; 71: 315-326
Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients.
J Am Soc Nephrol. 2003; 14: 1889-1896
Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients.
Transplantation. 2003; 76: 1233-1235
Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.
Transplantation. 2004; 78: 1182-1187
Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation.
Transpl Int. 2012; 25: 471-480
Do drug transporter (ABCB1) SNPs influence cyclosporine and tacrolimus dose requirements and renal allograft outcome in the posttransplantation period?.
J Clin Pharmacol. 2011; 51: 603-615
Long-term clinical impact of adaptation of initial tacrolimus dosing to CYP3A5 genotype.
Am J Transpl. 2016; 16: 2670-2675
Role of P-glycoprotein in chronic cyclosporine nephrotoxicity and its relationship to intrarenal angiotensin II deposits.
Transpl Proc. 1998; 30: 2014-2016
Expression of multidrug resistance P-glycoprotein in kidney allografts from cyclosporine A-treated patients.
Kidney Int. 2001; 60: 156-166
Elevated blood concentrations of calcineurin inhibitors during diarrheal episode in pediatric liver transplant recipients: involvement of the suppression of intestinal cytochrome P450 3A and P-glycoprotein.
Pediatr Transpl. 2005; 9: 315-323
Acute calcineurin inhibitor overdose: analysis of cases reported to a national poison center between 1995 and 2011.
Am J Transplant. 2013; 13: 786-795
Using known drug interactions to manage supratherapeutic calcineurin inhibitor concentrations.
Clin Transpl. 2017; 31https://doi.org/10.1111/ctr.13098
The nephrologist’s guide to cannabis and cannabinoids.
Curr Opin Nephrol Hypertens. 2020; 29: 248-257
Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review.
Drug Metab Rev. 2014; 46: 86-95
Evidence of a clinically significant drug-drug interaction between cannabidiol and tacrolimus [published online ahead of print April 23, 2019].
Am J Transpl. 2019; https://doi.org/10.1111/ajt.15398
Inhibition of cyclosporine and tetrahydrocannabinol metabolism by cannabidiol in mouse and human microsomes.
Xenobiotica. 1996; 26: 275-284
Bioprinting of 3D convoluted renal proximal tubules on perfusable chips.
Sci Rep. 2016; 6: 34845https://doi.org/10.1038/srep34845
Chronic renal failure after transplantation of a nonrenal organ.
N Engl J Med. 2003; 349: 931-940
Dissociation of glomerular filtration rate from tubulointerstitial fibrosis in experimental chronic cyclosporine nephropathy: role of sodium intake.
J Am Soc Nephrol. 1993; 4: 214-221
Low-salt diet and cyclosporine nephrotoxicity: changes in kidney cell metabolism.
J Proteome Res. 2012; 11: 5135-5144
Pathogenesis of cyclosporine nephropathy: roles of angiotensin II and osteopontin.
J Am Soc Nephrol. 1995; 6: 1186-1196
Enhancement of FK506 nephrotoxicity by sodium depletion in an experimental rat model.
Transplantation. 1994; 57: 483-489
Cellular proliferation and macrophage influx precede interstitial fibrosis in cyclosporine nephrotoxicity.
Kidney Int. 1995; 48: 439-448
Cyclosporine A induced arteriolopathy in a rat model of chronic cyclosporine nephropathy.
Kidney Int. 1995; 48: 431-438
Evolution and pathophysiology of renal-transplant glomerulosclerosis.
Transplantation. 2004; 78: 461-468
Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology.
Transplantation. 2004; 78: 557-565
Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy.
Kidney Int. 1996; 50: 1641-1650
Treatment of hypertension after renal transplantation: long-term efficacy of verapamil, enalapril, and doxazosin.
Kidney Int Suppl. 1998; 54: S130-S134
Dihydropyridine calcium antagonists and renal function in hypertensive kidney transplant recipients.
J Hypertens. 2000; 18: 1115-1119
Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion.
Kidney Int. 1993; 43: 706-711
Converting-enzyme inhibitor versus calcium antagonist in cyclosporine-treated renal transplants.
Kidney Int. 1993; 43: 419-425
Prevention of experimental cyclosporin-induced interstitial fibrosis by losartan and enalapril.
Am J Physiol. 1995; 269: F491-F499
Losartan decreases plasma levels of TGF-beta1 in transplant patients with chronic allograft nephropathy.
Kidney Int. 1999; 56: 714-719
Renin-angiotensin system blockade and long-term clinical outcomes in kidney transplant recipients: a meta-analysis of randomized controlled trials.
Am J Kidney Dis. 2017; 69: 78-86
Predictive usefulness of urinary biomarkers for the identification of cyclosporine A-induced nephrotoxicity in a rat model.
PLoS One. 2014; 9: e103660https://doi.org/10.1371/journal.pone.0103660
Safe conversion from tacrolimus to belatacept in high immunologic risk kidney transplant recipients with allograft dysfunction.
Am J Transpl. 2015; 15: 2726-2731
Electrolyte and acid-base disorders in the renal transplant recipient.
Front Med (Lausanne). 2018; 5: 261https://doi.org/10.3389/fmed.2018.00261
Hyponatraemia and hyperkalaemia are more frequent in renal transplant recipients treated with tacrolimus than with cyclosporin. Further evidence for differences between cyclosporin and tacrolimus nephrotoxicities.
Nephrol Dial Transpl. 2004; 19: 444-450
Effects of cyclosporine on the renin-angiotensin-aldosterone system and potassium excretion in renal transplant recipients.
Arch Intern Med. 1985; 145: 505-508
Studies to determine the basis for hyperkalemia in recipients of a renal transplant who are treated with cyclosporine.
J Am Soc Nephrol. 1992; 2: 1279-1284
Potassium modulates electrolyte balance and blood pressure through effects on distal cell voltage and chloride.
Cell Metab. 2015; 21: 39-50
Cyclosporin A inhibits apical secretory K+ channels in rabbit cortical collecting tubule principal cells.
Kidney Int. 1993; 44: 974-984
Hyperkalemia in cyclosporin-treated renal allograft recipients.
Lancet. 1983; 2: 370-372
Aldosterone resistance in kidney transplantation is in part induced by a down-regulation of mineralocorticoid receptor expression.
Clin Transpl. 2004; 18: 186-192
Hyperchloremic metabolic acidosis with high serum potassium in renal transplant recipients: a cyclosporine A associated side effect.
Clin Nephrol. 1986; 25: 245-248
Serum potassium concentrations in cyclosporine- and azathioprine-treated renal transplant patients.
Nephron. 1985; 40: 280-285
Calcineurin dephosphorylates Kelch-like 3, reversing phosphorylation by angiotensin II and regulating renal electrolyte handling.
Proc Natl Acad Sci U S A. 2019; 116: 3155-3160
KLHL3 regulates paracellular chloride transport in the kidney by ubiquitination of claudin-8.
Proc Natl Acad Sci U S A. 2015; 112: 4340-4345
Fludrocortisone therapy in renal transplant recipients with persistent hyperkalemia.
Case Rep Transpl. 2012; 2012: 586859https://doi.org/10.1155/2012/586859
Role of fludrocortisone in the management of tacrolimus-induced hyperkalemia in a renal transplant recipient.
Saudi J Kidney Dis Transpl. 2014; 25: 149-151
Cyclosporine nephrotoxicity and early posttransplant hyperkalemia in living-donor renal recipients: report of 4 cases.
Exp Clin Transpl. 2014; 12: 479-483
Clinical analysis of hyperkalemic renal tubular acidosis caused by calcineurin inhibitors in solid organ transplant recipients.
J Clin Pharm Ther. 2017; 42: 122-124
Fludrocortisone as a new tool for managing tubulopathy after pediatric renal transplantation: a series of cases.
Pediatr Nephrol. 2014; 29: 2061-2064
Fludrocortisone—a treatment for tubulopathy post-paediatric renal transplantation: a national paediatric nephrology unit experience.
Pediatr Transpl. 2018; 22: 1-5
Fludrocortisone is effective in the management of tacrolimus-induced hyperkalemia in liver transplant recipients.
Transpl Proc. 2011; 43: 2664-2668
Metabolic acidosis and long-term clinical outcomes in kidney transplant recipients.
J Am Soc Nephrol. 2017; 28: 1886-1897
Metabolic acidosis 1 year following kidney transplantation and subsequent cardiovascular events and mortality: an observational cohort study.
Am J Kidney Dis. 2019; 73: 476-485
Evidence that the inhibition of Na+/K(+)-ATPase activity by FK506 involves calcineurin.
Kidney Int. 1994; 46: 647-652
Nephron segment-specific inhibition of Na+/K(+)-ATPase activity by cyclosporin A.
Kidney Int. 1993; 43: 246-251
Cyclosporin A produces distal renal tubular acidosis by blocking peptidyl prolyl cis-trans isomerase activity of cyclophilin.
Am J Physiol Renal Physiol. 2005; 288: F40-F47
“I don’t get no respect”: the role of chloride in acute kidney injury.
Am J Physiol Renal Physiol. 2019; 316: F587-F605
Bicarbonate supplementation slows progression of CKD and improves nutritional status.
J Am Soc Nephrol. 2009; 20: 2075-2084
Preservation of kidney function in kidney transplant recipients by alkali therapy (Preserve-Transplant Study): rationale and study protocol.
BMC Nephrol. 2018; 19: 177https://doi.org/10.1186/s12882-018-0956-8
Determinants of urinary calcium and uric acid excretion in children after renal transplantation.
Pediatr Transpl. 2007; 11: 716-720
Hypocitraturia as a risk factor for nephrocalcinosis after kidney transplantation.
Pediatr Nephrol. 2005; 20: 652-656
Downregulation of Ca(2+) and Mg(2+) transport proteins in the kidney explains tacrolimus (FK506)-induced hypercalciuria and hypomagnesemia.
J Am Soc Nephrol. 2004; 15: 549-557
Cyclosporine A-induced hypercalciuria in calbindin-D28k knockout and wild-type mice.
Kidney Int. 2002; 62: 2055-2061
Hypomagnesemia and renal magnesium wasting in renal transplant recipients receiving cyclosporine.
Am J Med. 1987; 83: 693-699
Reduced erythrocyte and leukocyte magnesium is associated with cyclosporin treatment and hypertension in renal transplant patients.
Nephrol Dial Transpl. 1992; 7: 251-255
Cyclosporin-induced renal magnesium leak in renal transplant patients.
Nephrol Dial Transpl. 1990; 5: 812-815
Serum magnesium after kidney transplantation: a systematic review.
Nutrients. 2018; 10: 729https://doi.org/10.3390/nu10060729
Hypomagnesemia linked to new-onset diabetes mellitus after kidney transplantation: a systematic review and meta-analysis.
Endocr Res. 2016; 41: 142-147
Serum magnesium and related factors in long-term renal transplant recipients: an observational study.
Transpl Proc. 2017; 49: 799-802
Cyclosporin-induced hypomagnesaemia and renal magnesium wasting in rats.
Clin Sci (Lond). 1988; 75: 509-514
Role of hypomagnesemia in chronic cyclosporine nephropathy.
Transplantation. 2002; 73: 340-347
Hyperuricemia after renal transplantation.
Am J Surg. 1988; 156: 397-400
The incidence of gout in renal transplant recipients.
Am J Kidney Dis. 1987; 10: 369-372
Hyperuricemia and gout among heart transplant recipients receiving cyclosporine.
Am J Med. 1992; 92: 141-146
Hyperuricemia and gout in renal allograft recipients.
Transpl Proc. 1992; 24: 1773-1774
Cyclosporine-induced hyperuricemia and gout.
N Engl J Med. 1989; 321: 287-292
Hyperuricemia at 1 year after renal transplantation, its prevalence, associated factors, and graft survival.
Transplantation. 2012; 94: 145-151
Use of uric acid-lowering agents limits experimental cyclosporine nephropathy.
Nephron Exp Nephrol. 2012; 120: e12-e19
Trends in the causes of death among kidney transplant recipients in the United States (1996-2014).
Am J Nephrol. 2018; 48: 472-481
Hypertension after kidney transplantation.
Am J Kidney Dis. 2004; 43: 1071-1081
Assessment and management of hypertension in transplant patients.
J Am Soc Nephrol. 2015; 26: 1248-1260
Pathogenesis of calcineurin inhibitor-induced hypertension.
J Nephrol. 2012; 25: 269-275
Calcineurin inhibitors and hypertension: a role for pharmacogenetics?.
Pharmacogenomics. 2014; 15: 1243-1251
Effect of cyclosporine on blood pressure.
Cochrane Database Syst Rev. 2010; 1: CD007893https://doi.org/10.1002/14651858.CD007893.pub2
Hypertension in cyclosporine-treated renal transplant recipients is sodium dependent.
Am J Med. 1988; 85: 134-138
Inhibition of calcineurin phosphatase promotes exocytosis of renin from juxtaglomerular cells.
Kidney Int. 2010; 77: 110-117
The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension.
Nat Med. 2011; 17: 1304-1309
NaCl cotransporter abundance in urinary vesicles is increased by calcineurin inhibitors and predicts thiazide sensitivity.
PLoS One. 2017; 12: e0176220
Chlorthalidone versus amlodipine for hypertension in kidney transplant recipients treated with tacrolimus: a randomized crossover trial.
Am J Kidney Dis. 2017; 69: 796-804
Renal deletion of 12 kDa FK506-binding protein attenuates tacrolimus-induced hypertension.
J Am Soc Nephrol. 2016; 27: 1456-1464
Cyclosporine metabolic side effects: association with the WNK4 system.
Eur J Clin Invest. 2011; 41: 1113-1120
Calcineurin-inhibition results in upregulation of local renin and subsequent vascular endothelial growth factor production in renal collecting ducts.
Transplantation. 2016; 100: 325-333
Ciclosporin-induced hypertension is associated with increased sodium transporter of the loop of Henle (NKCC2).
Nephrol Dial Transpl. 2007; 22: 2810-2816
Calcineurin inhibitor cyclosporine A activates renal Na-K-Cl cotransporters via local and systemic mechanisms.
Am J Physiol Ren Physiol. 2017; 312: F489-F501
Calcineurin and sorting-related receptor with A-type repeats interact to regulate the renal Na(+)-K(+)-2Cl(-) cotransporter.
J Am Soc Nephrol. 2016; 27: 107-119
Dyslipidemia following kidney transplantation: diagnosis and treatment.
Curr Diab Rep. 2009; 9: 305-311
Lipid profile during azathioprine or mycophenolate mofetil combinations with cyclosporine and steroids.
Transpl Proc. 2007; 39: 135-137
Compared effect of immunosuppressive drugs cyclosporine A and rapamycin on cholesterol homeostasis key enzymes CYP27A1 and HMG-CoA reductase.
Basic Clin Pharmacol Toxicol. 2007; 100: 392-397
Effects of cyclosporine therapy on plasma lipoprotein levels.
JAMA. 1989; 262: 53-56
Cyclosporine, low-density lipoprotein, and cholesterol.
Mayo Clin Proc. 1988; 63: 1012-1021
Cyclosporine A and Rapamycin induce in vitro cholesteryl ester transfer protein activity, and suppress lipoprotein lipase activity in human plasma.
Int J Pharm. 2008; 358: 219-223
Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease.
Kidney Inter Suppl. 2013; 3: 259-305
Dyslipidemia and its therapeutic challenges in renal transplantation.
Am J Transpl. 2012; 12: 1975-1982
Smith MEB, Lee NJ, Haney E, et al. Drug Class Review: HMGCoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin: Final Report Update 5. Portland, OR: Oregon Health & Science University; November 2009. https://www.ncbi.nlm.nih.gov/books/NBK47273/. Accessed September 7, 2019.
Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients.
Cochrane Database Syst Rev. 2005; 4: CD003961https://doi.org/10.1002/14651858.CD003961.pub2
New-onset diabetes after renal transplantation: risk assessment and management.
Diabetes Care. 2012; 35: 181-188
Posttransplantation hypomagnesemia and its relation with immunosuppression as predictors of new-onset diabetes after transplantation.
Am J Transpl. 2009; 9: 2140-2149
Calcineurin/NFAT signalling regulates pancreatic beta-cell growth and function.
Nature. 2006; 443: 345-349
Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancreatic beta-cell.
Transplantation. 1995; 59: 1606-1613
Early basal insulin therapy decreases new-onset diabetes after renal transplantation.
J Am Soc Nephrol. 2012; 23: 739-749
A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group.
Transplantation. 1997; 63: 977-983
Neurotoxicity of calcineurin inhibitors: impact and clinical management.
Transpl Int. 2000; 13: 313-326
Neurotoxicity of immunosuppressive therapies in organ transplantation.
Maedica (Buchar). 2013; 8: 170-175
Neurotoxicity of immunosuppressive drugs.
Liver Transpl. 2001; 7: 937-942
A reversible posterior leukoencephalopathy syndrome.
N Engl J Med. 1996; 334: 494-500
Clinical spectrum of reversible posterior leukoencephalopathy syndrome.
Arch Neurol. 2008; 65: 205-210
Reduction in gingival overgrowth associated with conversion from cyclosporin A to tacrolimus.
J Clin Periodontol. 2000; 27: 144-148
Drug-induced gingival overgrowth: the nemesis of gingiva unravelled.
J Indian Soc Periodontol. 2013; 17: 182-187
Cyclosporin A-induced hair growth in mice is associated with inhibition of calcineurin-dependent activation of NFAT in follicular keratinocytes.
Am J Physiol Cell Physiol. 2003; 284: C1593-C1603
Partial response of severe alopecia areata to cyclosporine A.
Dermatology. 1999; 199: 67-69
Tacrolimus-induced alopecia in female kidney-pancreas transplant recipients.
Transplantation. 2005; 80: 1546-1549